Interference No. 103,675
intermediates for preparing the aforementioned group of compounds.
The compounds are believed to function by promoting the assembly of
stable microtubules from tubulin. Tubulin is the major constituent
of microtubules which are hollow cylinders that serve as part of
the skeletal system for cells and are crucial to a number of vital
functions, including mitosis. When the compounds bind to tubulin,
the microtubules are stabilized against depolymerization and, thus,
inhibit mitosis. The compounds are derivatives of taxol3, a well-
known compound useful in the treatment of ovarian and breast
cancer.
BACKGROUND
This interference was declared on October 24, 1995, and was
captioned Chen et al. v. Bouchard et al. based on the parties’
respective effective filing dates. On February 18, 1999, the
interference was redeclared by the Administrative Patent Judge
(APJ) to add a third party, Hester et al. (Application Serial
Number 08/454,210, filed on June 9, 1995) as a second junior party
(see Paper Number 158). On July 9, 1999, the APJ redeclared the
interference to reflect her decision authorizing Hester et al. to
add claims to their involved application to be designated as
corresponding to Count 2 and Count 3A (see paper Number 180). On
October 29, 1999, the APJ redeclared the interference to reflect
3 Taxol is the trademark for a proprietary product of the
Bristol-Myers-Squibb Company and is synthetically prepared
paclitaxel. Paclitaxel is naturally obtained from the bark of the
Pacific yew tree.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007